Although organic nitrates have been used in cardiovascular therapy for
many years, various aspects of their pharmacology remain poorly under
stood. It is now known that organic nitrates produce nitric oxide (NO)
in vascular smooth muscle cells, catalyzed by a membrane-bound enzyme
that is not glutathione-S-transferase. Other nitrovasodilators, such
as organic nitrites, sodium nitroprusside, and S-nitrosothiols, do not
utilize the same enzyme for NO generation. The short-term hemodynamic
action of various organic nitrates has been shown to be related to th
eir pharmacokinetics, but their long-term therapeutic effects are limi
ted by the development of pharmacologic tolerance. Nitrate sensitivity
in patients can be restored dally after a nitrate-free period of 8-12
hours. Coadministration of nitrates with other vasodilators, such as
captopril and hydralazine, may avoid the development of nitrate tolera
nce in patients with congestive heart failure.